ACT REPAGLINIDE 1 MG — DIN 02321483
REPAGLINIDE : 1 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is ACT REPAGLINIDE?
ACT REPAGLINIDE 1 MG contains REPAGLINIDE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02321483, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 03-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ACT REPAGLINIDE used for?
Adjunct to diet and exercise for type 2 diabetes; in combination with metformin or rosiglitazone when monotherapy and diet/exercise are inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Repaglinide cost around the world?
Repaglinide is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 8 | 40 | EUR███.██ |
| United States | acquisition | 3 | 17 | USD███.██ |
| Czechia | max producer price (ex-factory) | 3 | 9 | CZK███.██ |
| United Arab Emirates | public | 3 | 6 | AED███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 6 | MAD███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 4 | EUR███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
100 pack listings across 39 brand entries and 9 price bases, refreshed 05 Sep 2026. Ranges span every Repaglinide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Repaglinide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Repaglinide, across 27 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 3 | 3 | AURO-REPAGLINIDE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP REPAGLINIDE | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | REPAGLINIDE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ REPAGLINIDE | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 0 | ACT REPAGLINIDE, TEVA-REPAGLINIDE | No marketed DIN |
| APOTEX INC | 3 | 0 | APO-REPAGLINIDE | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | MYLAN-REPAGLINIDE | No marketed DIN |
| NOVO NORDISK CANADA INC | 3 | 0 | GLUCONORM 0.5MG, GLUCONORM 1.0MG, GLUCONORM 2.0MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (refers to Section 21 which is not fully visible), but strengths are 0.5 mg, 1 mg, and 2 mg. |
| Storage | Not explicitly detailed in the provided text (refers to Section 20 which is not fully visible). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Repaglinide |
|---|---|
| ATC code | A10BX02 |
| AHFS class | 68:20.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02321483 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2321483 |
| Brand name | ACT REPAGLINIDE |
| Generic / active ingredient | REPAGLINIDE : 1 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | A10BX02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BX |
| Current status | DORMANT |
| Status date | 03-Jul-2024 |
| Original market date | 2010-10-18 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Take before meals (2, 3, or 4 times daily). If a meal is missed or delayed, the dose should be skipped or delayed. Titrate based on blood glucose response.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; diabetic ketoacidosis; Type 1 diabetes; severe liver disease; concomitant use of gemfibrozil or clopidogrel.
Warnings and precautions
Can induce hypoglycemia. Associated with increased CV mortality (general class warning). Use caution in hepatic/renal impairment and elderly. Loss of glycemic control during stress/infection.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 27 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-REPAGLINIDE | 2 MG | TABLET | AURO PHARMA INC | MARKETED | 02424274 |
| AURO-REPAGLINIDE | 1 MG | TABLET | AURO PHARMA INC | MARKETED | 02424266 |
| AURO-REPAGLINIDE | 0.5 MG | TABLET | AURO PHARMA INC | MARKETED | 02424258 |
| JAMP REPAGLINIDE | 0.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02354926 |
| JAMP REPAGLINIDE | 2 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02354942 |
| JAMP REPAGLINIDE | 1 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02354934 |
| REPAGLINIDE | 0.5 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02415968 |
| REPAGLINIDE | 1 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02415976 |
| REPAGLINIDE | 2 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02415984 |
| SANDOZ REPAGLINIDE | 1 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02357461 |
2 · Same class — other molecules in ATC A10BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tirzepatide | MOUNJARO · MOUNJARO KWIKPEN · ZEPBOUND KWIKPEN | 24 | 18 | Yes |
| Repaglinide | ACT REPAGLINIDE · APO-REPAGLINIDE · AURO-REPAGLINIDE · GLUCONORM 0.5MG · +7 more | 27 | 12 | Yes |
| Nateglinide | STARLIX 120MG · STARLIX 180MG · STARLIX 60MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · +1 more | 112 | 23 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACT REPAGLINIDE called?
The same molecule, Repaglinide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NOVONORM | Latin | Czechia, Morocco |
| ENYGLID | Latin | Czechia |
| VATINID | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.